Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer

Molecular and Cellular Proteomics

Volumn 11, Issue 12, 2012, Pages 1870-1884

  Kim, Yunee ^a   Ignatchenko, Vladimir ^b   Yao, Cindy Q ^a,c   Kalatskaya, Irina ^c   Nyalwidhe, Julius O ^d   Lance, Raymond S ^d   Gramolini, Anthony O ^a   Troyer, Dean A ^d   Stein, Lincoln D ^c   Boutros, Paul C ^c   Medin, Jeffrey A ^a,b   Semmes, O John ^d   Drake, Richard R ^d,e   Kislinger, Thomas ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ADAMTS1 PROTEIN; CREATINE KINASE BB; LIPOCORTIN 1; MEMBRANE METALLOENDOPEPTIDASE; MYOSIN; MYOSIN 9; PARKINSON PROTEIN 7; PIGMENT EPITHELIUM DERIVED FACTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE S; STRATIFIN; SYNTHETIC PEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSGLUTAMINASE 4; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; FOLLOW UP; HUMAN; ISOTOPE LABELING; MALE; MASS SPECTROMETER; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE FLUID; PROSTATE SECRETION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENT CANCER; WESTERN BLOTTING;

14-3-3 PROTEINS; EXONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOTOPE LABELING; MALE; ONCOGENE PROTEINS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; PROTEIN ARRAY ANALYSIS; PROTEOME; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSGLUTAMINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84870679496     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M112.017889     Document Type: Article

References (83)

1. Greene, K. L., Cowan, J. E., Cooperberg, M. R., Meng, M. V., DuChane, J., and Carroll, P. R. (2005) Who is the average patient presenting with prostate cancer? Urology 66, 76-82 (Pubitemid 41356563)
2. Ploussard, G., and de la Taille, A. (2010) Urine biomarkers in prostate cancer. Nat. Rev. Urol. 7, 101-109
3. Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L. J., Recker, F., Berenguer, A., Määttänen, L., Bangma, C. H., Aus, G., Villers, A., Rebillard, X., van der Kwast, T., Blijenberg, B. G., Moss, S. M., de Koning, H. J., and Auvinen, A. (2009) Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328
4. Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., and Partin, A. W. (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294, 433-439 (Pubitemid 41124175)
5. Penney, K. L., Sinnott, J. A., Fall, K., Pawitan, Y., Hoshida, Y., Kraft, P., Stark, J. R., Fiorentino, M., Perner, S., Finn, S., Calza, S., Flavin, R., Freedman, M. L., Setlur, S., Sesso, H. D., Andersson, S. O., Martin, N., Kantoff, P. W., Johansson, J. E., Adami, H. O., Rubin, M. A., Loda, M., Golub, T. R., Andrén, O., Stampfer, M. J., and Mucci, L. A. (2011) mRNA expression signature of Gleason grade predicts lethal prostate cancer. J. Clin. Oncol. 29, 2391-2396
6. Abate-Shen, C., and Shen, M. M. (2000) Molecular genetics of prostate cancer. Genes Dev. 14, 2410-2434
7. Chung, B. I., Tarin, T. V., Ferrari, M., and Brooks, J. D. (2011) Comparison of prostate cancer tumor volume and percent cancer in prediction of biochemical recurrence and cancer specific survival. Urol. Oncol. 29, 314-318
8. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Kaplan, I., Beard, C. J., Tomaszewski, J. E., Renshaw, A. A., Loughlin, K. R., Richie, J. P., and Wein, A. (1998) Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. J. Clin. Oncol. 16, 3094-3100 (Pubitemid 28417431)
9. Yossepowitch, O., Eggener, S. E., Bianco, F. J., Jr., Carver, B. S., Serio, A., Scardino, P. T., and Eastham, J. A. (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J. Urol. 178, 493-499; discussion 499
10. Han, M., Partin, A. W., Pound, C. R., Epstein, J. I., and Walsh, P. C. (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 28, 555-565 (Pubitemid 32916759)
11. Roehl, K. A., Han, M., Ramos, C. G., Antenor, J. A., and Catalona, W. J. (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J. Urol. 172, 910-914 (Pubitemid 39096421)
12. Hull, G. W., Rabbani, F., Abbas, F., Wheeler, T. M., Kattan, M. W., and Scardino, P. T. (2002) Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J. Urol. 167, 528-534 (Pubitemid 34074521)
13. Amling, C. L., Blute, M. L., Bergstralh, E. J., Seay, T. M., Slezak, J., and Zincke, H. (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J. Urol. 164, 101-105 (Pubitemid 30434268)
14. Boorjian, S. A., Thompson, R. H., Tollefson, M. K., Rangel, L. J., Bergstralh, E. J., Blute, M. L., and Karnes, R. J. (2011) Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur. Urol. 59, 893-899
15. Stephenson, A. J., and Kattan, M. W. (2006) Nomograms for prostate cancer. BJU Int. 98, 39-46 (Pubitemid 43885501)
16. Chodak, G. W., and Warren, K. S. (2006) Watchful waiting for prostate cancer: a review article. Prostate Cancer Prostatic Dis. 9, 25-29 (Pubitemid 43378864)
17. Klotz, L. (2008) Active surveillance for prostate cancer: trials and tribulations. World J. Urol. 26, 437-442
18. Drake, R. R., White, K. Y., Fuller, T. W., Igwe, E., Clements, M. A., Nyalwidhe, J. O., Given, R. W., Lance, R. S., and Semmes, O. J. (2009) Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J. Proteomics 72, 907-917
19. Drake, R. R., Elschenbroich, S., Lopez-Perez, O., Kim, Y., Ignatchenko, V., Ignatchenko, A., Nyalwidhe, J. O., Basu, G., Wilkins, C. E., Gjurich, B., Lance, R. S., Semmes, O. J., Medin, J. A., and Kislinger, T. (2010) In-depth proteomic analyses of direct expressed prostatic secretions. J. Proteome Res. 9, 2109-2116
20. Principe, S., Kim, Y., Fontana, S., Ignatchenko, V., Nyalwidhe, J. O., Lance, R. S., Troyer, D. A., Alessandro, R., Semmes, O. J., Kislinger, T., Drake, R. R., and Medin, J. A. (2012) Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J. Proteome Res. 11, 2386-2396
21. Choi, H., Fermin, D., and Nesvizhskii, A. I. (2008) Significance analysis of spectral count data in label-free shotgun proteomics. Mol. Cell Proteomics 7, 2373-2385
22. Taylor, P., Nielsen, P. A., Trelle, M. B., Horning, O. B., Andersen, M. B., Vorm, O., Moran, M. F., and Kislinger, T. (2009) Automated 2D peptide separation on a 1D nano-LC-MS system. J. Proteome Res. 8, 1610-1616
23. Washburn, M. P., Wolters, D., and Yates, J. R., 3rd (2001) Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19, 242-247 (Pubitemid 32220565)
24. Cox, B., Kotlyar, M., Evangelou, A. I., Ignatchenko, V., Ignatchenko, A., Whiteley, K., Jurisica, I., Adamson, S. L., Rossant, J., and Kislinger, T. (2009) Comparative systems biology of human and mouse as a tool to guide the modeling of human placental pathology. Mol. Syst. Biol. 5, 279
25. Gortzak-Uzan, L., Ignatchenko, A., Evangelou, A. I., Agochiya, M., Brown, K. A., St Onge, P., Kireeva, I., Schmitt-Ulms, G., Brown, T. J., Murphy, J., Rosen, B., Shaw, P., Jurisica, I., and Kislinger, T. (2008) A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J. Proteome Res. 7, 339-351 (Pubitemid 351171148)
26. Sodek, K. L., Evangelou, A. I., Ignatchenko, A., Agochiya, M., Brown, T. J., Ringuette, M. J., Jurisica, I., and Kislinger, T. (2008) Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT). Mol. Biosyst. 4, 762-773 (Pubitemid 351871749)
27. Pavelka, N., Fournier, M. L., Swanson, S. K., Pelizzola, M., Ricciardi-Castagnoli, P., Florens, L., and Washburn, M. P. (2008) Statistical similarities between transcriptomics and quantitative shotgun proteomics data. Mol. Cell. Proteomics 7, 631-644 (Pubitemid 351597476)
28. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57
29. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13
30. Wu, G., Feng, X., and Stein, L. (2010) A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 11, R53
31. Gross, J. L., and Yellen, J. (1999) Graph theory and its applications, CRC Press, Boca Raton, Fla.
32. Girvan, M., and Newman, M. E. (2002) Community structure in social and biological networks. Proc. Natl. Acad. Sci. U.S.A. 99, 7821-7826 (Pubitemid 34650963)
33. Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., and Ideker, T. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (Pubitemid 37428274)
34. Wu, C., Orozco, C., Boyer, J., Leglise, M., Goodale, J., Batalov, S., Hodge, C. L., Haase, J., Janes, J., Huss, J. W., 3rd, and Su, A. I. (2009) BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 10, R130
35. Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., Wernerus, H., Bjorling, L., and Ponten, F. (2010) Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 28, 1248-1250
36. Sardana, G., Jung, K., Stephan, C., and Diamandis, E. P. (2008) Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res. 7, 3329-3338
37. Li, R., Guo, Y., Han, B. M., Yan, X., Utleg, A. G., Li, W., Tu, L. C., Wang, J., Hood, L., Xia, S., and Lin, B. (2008) Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Proteomics Clin. Appl. 2, 543-555 (Pubitemid 351566262)
38. Adachi, J., Kumar, C., Zhang, Y., Olsen, J. V., and Mann, M. (2006) The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 7, R80
39. Pilch, B., and Mann, M. (2006) Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol. 7, R40
40. Batruch, I., Lecker, I., Kagedan, D., Smith, C. R., Mullen, B. J., Grober, E., Lo, K. C., Diamandis, E. P., and Jarvi, K. A. (2011) Proteomic analysis of seminal plasma from normal volunteers and post-vasectomy patients identifies over 2000 proteins and candidate biomarkers of the urogenital system. J. Proteome Res. 10, 941-953
41. Alexander, H., Stegner, A. L., Wagner-Mann, C., Du Bois, G. C., Alexander, S., and Sauter, E. R. (2004) Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin. Cancer Res. 10, 7500-7510 (Pubitemid 39557511)
42. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., and MacCoss, M. J. (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966-968
43. Elschenbroich, S., Ignatchenko, V., Clarke, B., Kalloger, S. E., Boutros, P. C., Gramolini, A. O., Shaw, P., Jurisica, I., and Kislinger, T. (2011) In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. J. Proteome Res. 10, 2286-2299
44. Han, B., and Higgs, R. E. (2008) Proteomics: from hypothesis to quantitative assay on a single platform. Guidelines for developing MRM assays using ion trap mass spectrometers. Brief Funct. Genomic Proteomic 7, 340-354
45. Lange, V., Picotti, P., Domon, B., and Aebersold, R. (2008) Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 4, 222
46. Hüttenhain, R., Soste, M., Selevsek, N., Röst, H., Sethi, A., Carapito, C., Farrah, T., Deutsch, E. W., Kusebauch, U., Moritz, R. L., Niméus-Malmström, E., Rinner, O., and Aebersold, R. (2012) Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci. Transl. Med. 4, 142-194
47. Anderson, N. L., and Anderson, N. G. (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845-867
48. Paulovich, A. G., Whiteaker, J. R., Hoofnagle, A. N., and Wang, P. (2008) The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. Proteomics Clin. Appl. 2, 1386-1402
49. Rifai, N., Gillette, M. A., and Carr, S. A. (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24, 971-983 (Pubitemid 44215392)
50. Dowling, P., Wormald, R., Meleady, P., Henry, M., Curran, A., and Clynes, M. (2008) Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis. J. Proteomics 71, 168-175 (Pubitemid 351915861)
51. Hu, S., Yu, T., Xie, Y., Yang, Y., Li, Y., Zhou, X., Tsung, S., Loo, R. R., Loo, J. R., and Wong, D. T. (2007) Discovery of oral fluid biomarkers for human oral cancer by mass spectrometry. Cancer Genomics Proteomics4, 55-64 (Pubitemid 46632026)
52. Zhao, T., Zeng, X., Bateman, N. W., Sun, M., Teng, P. N., Bigbee, W. L., Dhir, R., Nelson, J. B., Conrads, T. P., and Hood, B. L. (2012) Relative quantitation of proteins in expressed prostatic secretion with a stable isotope labeled secretome standard. J. Proteome Res. 11, 1089-1099
53. Addona, T. A., Shi, X., Keshishian, H., Mani, D. R., Burgess, M., Gillette, M. A., Clauser, K. R., Shen, D., Lewis, G. D., Farrell, L. A., Fifer, M. A., Sabatine, M. S., Gerszten, R. E., and Carr, S. A. (2011) A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat. Biotechnol. 29, 635-643
54. Whiteaker, J. R., Lin, C., Kennedy, J., Hou, L., Trute, M., Sokal, I., Yan, P., Schoenherr, R. M., Zhao, L., Voytovich, U. J., Kelly-Spratt, K. S., Krasnoselsky, A., Gafken, P. R., Hogan, J. M., Jones, L. A., Wang, P., Amon, L., Chodosh, L. A., Nelson, P. S., McIntosh, M. W., Kemp, C. J., and Paulovich, A. G. (2011) A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 29, 625-634
55. Woodson, K., O'Reilly, K. J., Hanson, J. C., Nelson, D., Walk, E. L., and Tangrea, J. A. (2008) The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J. Urol. 179, 508-511; discussion 511-502
56. Hessels, D., Klein Gunnewiek, J. M., van Oort, I., Karthaus, H. F., van Leenders, G. J., van Balken, B., Kiemeney, L. A., Witjes, J. A., and Schalken, J. A. (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 44, 8-15; discussion 15-16
57. Schostak, M., Schwall, G. P., Poznanovic, S., Groebe, K., Muller, M., Messinger, D., Miller, K., Krause, H., Pelzer, A., Horninger, W., Klocker, H., Hennenlotter, J., Feyerabend, S., Stenzl, A., and Schrattenholz, A. (2009) Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J. Urol. 181, 343-353
58. Roy, R., Louis, G., Loughlin, K. R., Wiederschain, D., Kilroy, S. M., Lamb, C. C., Zurakowski, D., and Moses, M. A. (2008) Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin. Cancer Res. 14, 6610-6617
59. Irani, J., Salomon, L., Soulie, M., Zlotta, A., de la Taille, A., Doré, B., and Millet, C. (2005) Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection. Urology 65, 533-537 (Pubitemid 40386004)
60. Bolduc, S., Lacombe, L., Naud, A., Grégoire, M., Fradet, Y., and Tremblay, R. R. (2007) Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol. Assoc. J. 1, 377-381
61. Sumitomo, M., Iwase, A., Zheng, R., Navarro, D., Kaminetzky, D., Shen, R., Georgescu, M. M., and Nanus, D. M. (2004) Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 5, 67-78 (Pubitemid 38121597)
62. Osman, I., Yee, H., Taneja, S. S., Levinson, B., Zeleniuch-Jacquotte, A., Chang, C., Nobert, C., and Nanus, D. M. (2004) Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin. Cancer Res. 10, 4096-4100 (Pubitemid 38812488)
63. De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Gronberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., and Nelson, W. G. (2007) Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7, 256-269 (Pubitemid 46486616)
64. Sfanos, K. S., and De Marzo, A. M. (2012) Prostate cancer and inflammation: the evidence. Histopathology 60, 199-215
65. Nonomura, N., Takayama, H., Nakayama, M., Nakai, Y., Kawashima, A., Mukai, M., Nagahara, A., Aozasa, K., and Tsujimura, A. (2011) Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 107, 1918-1922
66. Gannon, P. O., Poisson, A. O., Delvoye, N., Lapointe, R., Mes-Masson, A. M., and Saad, F. (2009) Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J. Immunol. Methods 348, 9-17
67. Fredolini, C., Meani, F., Luchini, A., Zhou, W., Russo, P., Ross, M., Patanarut, A., Tamburro, D., Gambara, G., Ornstein, D., Odicino, F., Ragnoli, M., Ravaggi, A., Novelli, F., Collura, D., D'Urso, L., Muto, G., Belluco, C., Pecorelli, S., Liotta, L., and Petricoin, E. F., 3rd (2010) Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. AAPS J. 12, 504-518
68. Longo, C., Patanarut, A., George, T., Bishop, B., Zhou, W., Fredolini, C., Ross, M. M., Espina, V., Pellacani, G., Petricoin, E. F., 3rd, Liotta, L. A., and Luchini, A. (2009) Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One 4, e4763
69. Tamburro, D., Fredolini, C., Espina, V., Douglas, T. A., Ranganathan, A., Ilag, L., Zhou, W., Russo, P., Espina, B. H., Muto, G., Petricoin, E. F., 3rd, Liotta, L. A., and Luchini, A. (2011) Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. J. Am. Chem. Soc. 133, 19178-19188
70. Roth, J. (2002) Protein N-glycosylation along the secretory pathway: relationship to organelle topography and function, protein quality control, and cell interactions. Chem. Rev. 102, 285-303
71. Tian, Y., Zhou, Y., Elliott, S., Aebersold, R., and Zhang, H. (2007) Solid-phase extraction of N-linked glycopeptides. Nat. Protoc. 2, 334-339 (Pubitemid 47040048)
72. Zhang, H., Li, X. J., Martin, D. B., and Aebersold, R. (2003) Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat. Biotechnol. 21, 660-666 (Pubitemid 36638093)
73. Anderson, N. L., Anderson, N. G., Haines, L. R., Hardie, D. B., Olafson, R. W., and Pearson, T. W. (2004) Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J. Proteome Res. 3, 235-244 (Pubitemid 38500990)
74. Anderson, N. L., Jackson, A., Smith, D., Hardie, D., Borchers, C., and Pearson, T. W. (2009) SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol. Cell. Proteomics 8, 995-1005
75. Zhou, H., Yuen, P. S., Pisitkun, T., Gonzales, P. A., Yasuda, H., Dear, J. W., Gross, P., Knepper, M. A., and Star, R. A. (2006) Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int. 69, 1471-1476
76. Mataija-Botelho, D., Murphy, P., Pinto, D. M., Maclellan, D. L., Langlois, C., and Doucette, A. A. (2009) A qualitative proteome investigation of the sediment portion of human urine: Implications in the biomarker discovery process. Proteomics Clin. Appl. 3, 95-105
77. Duijvesz, D., Luider, T., Bangma, C. H., and Jenster, G. (2011) Exosomes as biomarker treasure chests for prostate cancer. Eur. Urol. 59, 823-831
78. Nilsson, J., Skog, J., Nordstrand, A., Baranov, V., Mincheva-Nilsson, L., Breakefield, X. O., and Widmark, A. (2009) Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 100, 1603-1607
79. Chen, Y. T., Chen, H. W., Domanski, D., Smith, D. S., Liang, K. H., Wu, C. C., Chen, C. L., Chung, T., Chen, M. C., Chang, Y. S., Parker, C. E., Borchers, C. H., and Yu, J. S. (2012) Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J. Proteomics 75, 3529-3545
80. Zhi, W., Wang, M., and She, J. X. (2011) Selected reaction monitoring (SRM) mass spectrometry without isotope labeling can be used for rapid protein quantification. Rapid Commun. Mass Spectrom 25, 1583-1588
81. Fortin, T., Salvador, A., Charrier, J. P., Lenz, C., Lacoux, X., Morla, A., Choquet-Kastylevsky, G., and Lemoine, J. (2009) Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol. Cell. Proteomics 8, 1006-1015
82. Cima, I., Schiess, R., Wild, P., Kaelin, M., Schuffler, P., Lange, V., Picotti, P., Ossola, R., Templeton, A., Schubert, O., Fuchs, T., Leippold, T., Wyler, S., Zehetner, J., Jochum, W., Buhmann, J., Cerny, T., Moch, H., Gillessen, S., Aebersold, R., and Krek, W. (2011) Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 108, 3342-3347
83. Thongboonkerd, V. (2007) Practical points in urinary proteomics. J. Proteome Res. 6, 3881-3890